Correlation Between Zealand Pharma and Oncopeptides

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Zealand Pharma and Oncopeptides at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Zealand Pharma and Oncopeptides into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Zealand Pharma AS and Oncopeptides AB, you can compare the effects of market volatilities on Zealand Pharma and Oncopeptides and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Zealand Pharma with a short position of Oncopeptides. Check out your portfolio center. Please also check ongoing floating volatility patterns of Zealand Pharma and Oncopeptides.

Diversification Opportunities for Zealand Pharma and Oncopeptides

0.6
  Correlation Coefficient

Poor diversification

The 3 months correlation between Zealand and Oncopeptides is 0.6. Overlapping area represents the amount of risk that can be diversified away by holding Zealand Pharma AS and Oncopeptides AB in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Oncopeptides AB and Zealand Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Zealand Pharma AS are associated (or correlated) with Oncopeptides. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Oncopeptides AB has no effect on the direction of Zealand Pharma i.e., Zealand Pharma and Oncopeptides go up and down completely randomly.

Pair Corralation between Zealand Pharma and Oncopeptides

Assuming the 90 days trading horizon Zealand Pharma AS is expected to generate 0.71 times more return on investment than Oncopeptides. However, Zealand Pharma AS is 1.4 times less risky than Oncopeptides. It trades about 0.35 of its potential returns per unit of risk. Oncopeptides AB is currently generating about 0.08 per unit of risk. If you would invest  67,650  in Zealand Pharma AS on September 19, 2024 and sell it today you would earn a total of  12,250  from holding Zealand Pharma AS or generate 18.11% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Zealand Pharma AS  vs.  Oncopeptides AB

 Performance 
       Timeline  
Zealand Pharma AS 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Zealand Pharma AS has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's basic indicators remain healthy and the recent disarray on Wall Street may also be a sign of long period gains for the firm investors.
Oncopeptides AB 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Oncopeptides AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in January 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Zealand Pharma and Oncopeptides Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Zealand Pharma and Oncopeptides

The main advantage of trading using opposite Zealand Pharma and Oncopeptides positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Zealand Pharma position performs unexpectedly, Oncopeptides can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Oncopeptides will offset losses from the drop in Oncopeptides' long position.
The idea behind Zealand Pharma AS and Oncopeptides AB pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.

Other Complementary Tools

Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Stocks Directory
Find actively traded stocks across global markets
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum